GSK acquires Sierra Oncology for 1.9bn
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1281 entries already.
Entries by Thomas Gabrielczyk
Scientists print 3D cancer model
/in News/by Thomas GabrielczykA 3D tumour model developed by scientists enables drug screening in metastases
Affimed prices public offering to finance NK cell trials
/in News/by Thomas GabrielczykFollowing phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
/in News/by Thomas GabrielczykSwiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent swallows VMIC Ltd
/in News/by Thomas GabrielczykCatalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches 440 m private equity healthcare strategy
/in News/by Thomas GabrielczykAXA IM Alts, has launched a Global Health Strategy following a 18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
Bayer Leaps to invests 1.3bn externally
/in News/by Thomas GabrielczykGerman Bayer AG has announced it will channel at least 1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Avantium closes financing for FDCA plant
/in News/by Thomas GabrielczykAvantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.
Novo Holdings co-leads 40m Qure.ai financing
/in News/by Thomas GabrielczykDeep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
XNK Therapeutics AB raises 12.75m
/in News/by Thomas GabrielczykXNK Therapeutics AB has secured a private placement of 12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.